BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22538015)

  • 1. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
    Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
    Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
    Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W
    J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
    Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
    Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
    Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
    Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
    Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
    Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
    Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
    Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
    Burlison JA; Blagg BS
    Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
    Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.